Teva a Generic Giant With Biotech Bite

This podcast features Ann-Hunter van Kirk from Bloomberg Intelligence interviewing Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva Pharmaceuticals, about Teva's R&D, pipeline, and transformation from a generics company to an innovative powerhouse. They discuss the restructuring of Teva's R&D, key assets in their pipeline like Olanzapine LAI and Duviketug, their approach to asset selection, the role of partnerships and AI in drug development, and the balance between their generic and innovative businesses. The conversation also covers upcoming GDUFA negotiations and the importance of collaboration between commercial and R&D teams.